Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bronchial Thermoplasty Induced Changes in Blood Transcriptome Profile of Patients with Severe Asthma.

International journal of molecular sciences·2026

Same author

Socioeconomic inequalities in severe childhood asthma: results of a nationwide cohort.

ERJ open research·2026

Same author

ESCP best practice: development, implementation and evaluation of sick day guidance in primary care in the Netherlands.

International journal of clinical pharmacy·2026

Same author

Maternal smoking and CC-16: implications for lung development and COPD across the lifespan.

American journal of respiratory and critical care medicine·2025

Same author

Barriers and facilitators for effective sick day guidance implementation.

Journal of nephrology·2025

Same author

Estimated glomerular filtration rate in post COVID-19 patients at 3-6 months and 12-18 months after infection.

Renal failure·2025

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Pharmacogenetics and the pharmaceutical industry.

Jan A M Raaijmakers¹, Ellen S Koster, Anke-Hilse Maitland-van der Zee

¹Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, the Netherlands. j.a.m.raaijmakers@uu.nl

Current Pharmaceutical Design

|March 9, 2010

Summary

Pharmacogenetics enhances drug development by improving safety and efficacy, paving the way for personalized medicine. Future applications will integrate genetic insights with systems biology for a holistic view of disease and treatment.

Related Experiment Videos

Last Updated: Jun 15, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

Pharmacogenetics
Genomics
Systems Biology
Drug Development

Background:

Despite advances in human genome knowledge, direct therapeutic applications for diseases remain limited.
Pharmacogenetics offers valuable insights into pharmacotherapy, guiding drug development.
The pharmaceutical industry is increasingly incorporating pharmacogenetics into drug design.

Purpose of the Study:

To explore the current and future impact of pharmacogenetics on drug discovery and development.
To highlight key areas of pharmacogenetics application: safety, efficacy, and target identification.
To discuss the integration of pharmacogenetics with systems biology and personalized medicine.

Main Methods:

Review of current pharmacogenetic applications in drug development.
Analysis of industry trends and research directions in pharmacogenetics.
Exploration of the integration of pharmacogenetics within a systems biology framework.

Main Results:

Pharmacogenetics is crucial for improving drug safety and efficacy.
Patient selection based on pharmacogenetic data drives personalized medicine.
Emerging approaches integrate environmental and behavioral factors with genetic data.

Conclusions:

Pharmacogenetics is transforming drug development towards personalized medicine.
An integrated systems biology approach, including environmental factors, provides a comprehensive view of disease and treatment.
Collaboration between industry and academia is vital for advancing pharmacogenetics research.